USE OF A 27-GENE IMMUNO-ONCOLOGY (IO) ASSAY TO ASSOCIATE RESPONSE TO SINGLE-AGENT IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY IN ADVANCED-STAGE NSCLC PATIENTS FROM A LARGE CANADIAN COHORT

1David Saltman*, 2Nicole Croteau, 1Heather Lockyer, 3Rob Seitz, 3Frank McMahon, 3Jeremy Spille, 3Andrea Dickey, 3Matthew Varga, 3Kim McGregor, 3Tyler Nielsen, 3David Hout, 3Brock Schweitzer, 3Douglas Ross, 3David Gandara. 1BC Cancer, Victoria, Canada; 2The University of British Columbia, Victoria, Canada; 3Oncocyte Corporation, Nashville, TN, USA; 4UC Davis, Sacramento, CA, USA

Background Lung cancer is the leading cause of cancer-related deaths worldwide. The advent of ICIs specifically targeting programmed cell death protein-1 (PD-1), or its ligand (PD-L1) represents a major therapeutic advance that is now included in standard of care regimens for non-small-cell-lung cancer (NSCLC). PD-L1 expression measured by immunohistochemistry (IHC) staining is the current gold standard predictive biomarker for immune checkpoint inhibitor (ICI) therapy in NSCLC, however many factors beyond PD-L1 expression alone affect the outcome of ICI therapy. Evaluation of other factors to better inform clinical practice will reduce both the potential for adverse immune-related toxicities and expenditure on ineffective costly therapies while potentially identifying patients otherwise missed by PD-L1 staining. The 27-gene IO assay is a RT-qPCR based gene expression panel1 that was developed to classify the tumor immune microenvironment (TIME). It has been shown to be associated with response to ICI therapy in multiple tumor types including triple negative breast cancer, metastatic urothelial carcinoma, and NSCLC where the association was independent of PD-L1 status in patients treated either with monotherapy or combination therapy.2 Currently, BC Cancer measures PD-L1 status by IHC using the PD-L1 22C3 PharmDx assay and reports the tumor proportional score (TPS) to inform clinical decision. Patients with a TPS ≥ 50% may be eligible for first-line treatment with ICI monotherapy and those with < 50% TPS are eligible for second line or later ICI monotherapy. We established this retrospective study of ICI monotherapy treated NSCLC patients to assess the 27-gene IO assay as an informative biomarker for NSCLC ICI treatment decisions.

Methods This retrospective study is utilizing the BC Cancer Study Database to select approximately 150 patients with stage IIIIB or IV NSCLC treated with single-agent ICI therapy across four BC Cancer centers from 2017 forward (figure 1). Patients are selected based on availability of adequate biopsy specimens (FFPE with at least 20% tumor content), availability of PD-L1 IHC results or sufficient tissue to conduct staining, and for whom outcome data is available via chart review. RNA from patient samples is isolated from FFPE biopsies (either primary or metastatic sites) and those that yield ≥ 50ng RNA will be analyzed by the 27-gene IO assay to derive IO scores (IO positive or IO negative) based on previously defined thresholds.3 The association between patient outcomes on ICI monotherapy and IO scores and PD-L1 IHC will be reported and compared.

REFERENCES

Ethics Approval The University of British Columbia BC Cancer Research Ethics Board Chair, Vice-Chair or second Vice-Chair, has reviewed the above described research project, including associated documentation, and finds the research project acceptable on ethical grounds for research involving human subjects. All participants have provided informed consent before taking part in the study. REB Number H20-02635.

http://dx.doi.org/10.1136/jitc-2021-SITC2021.466